Superluminal Medicines Raises $60 Million Series B Led By BVF Partners
By Amit Chowdhry ● Yesterday at 10:15 AM
Superluminal Medicines has raised an oversubscribed $60 million Series B financing led by BVF Partners to advance its lead obesity program into clinical development and expand its AI-enabled drug discovery platform. New investors Deep Track Capital and Perceptive Advisors participated alongside existing investors RA Capital Management, Insight Partners, NVIDIA, Catalio Capital Management, Eli Lilly and Company, Cooley and Gaingels.